Psyence Biomedical Ltd.
PBM · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.07 | -57.70 | 0.00 |
| FCF Yield | -156.94% | -0.08% | -0.00% | -0.00% |
| EV / EBITDA | -3.66 | -76.51 | -127,214.33 | -455,539.15 |
| Quality | ||||
| ROIC | -54.49% | 524.51% | -0.53% | -0.13% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -3.69 | 0.06 | 21.22 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -26.87% | -467.95% | 38.08% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -5.98 | -0.19 | -0.43 | 1.94 |
| Interest Coverage | -395.15 | -51.98 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -22,400.89 | -855,243.67 | 0.00 | 0.00 |